Pub Date : 2022-01-01DOI: 10.33029/0206-4952-2022-43-5-536-547
M. Kuznetsova, V. Tereshchenko, Y. Shevchenko, M. Fisher, V. Kurilin, A. Alsalloum, S. Alrhmoun, Y. Akahori, H. Shiku, S. Sennikov
{"title":"Phenotypic and functional features of in vitro generated TCR-T cells specific for the tumor-associated antigen NY-ESO-1","authors":"M. Kuznetsova, V. Tereshchenko, Y. Shevchenko, M. Fisher, V. Kurilin, A. Alsalloum, S. Alrhmoun, Y. Akahori, H. Shiku, S. Sennikov","doi":"10.33029/0206-4952-2022-43-5-536-547","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-5-536-547","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69482292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.33029/0206-4952-2022-43-3-301-311
P. A. Talyzin, A. Myasnikov, S. Berns, M. Ilyina, A. Komazov, V. Lynyov, E. V. Ekusheva
Background. In vitro studies showed effective viral infection block in case of pretreatment with exogenous interferons. Interferon-gamma is a unique immune interferon, actively expressed in patients with acute respiratory viral infections (ARVI) and defending the body from severe infection course. Aim - to evaluate the safety and preventive effectiveness of nasal interferon-gamma protecting against ARVI, including COVID-19. Material and methods. The study enrolled 630 adult volunteers with a negative PCR test result for SARS-CoV-2, without respiratory symptoms and contraindications to interferongamma. Participants were randomized (1 : 1) into 2 groups: the study group - with the use of a prophylactic course of nasal interferon-gamma, and the group of comparison - without a course of prophylaxis. All participants were given a diary for daily monitor respiratory symptoms, adverse events, and record the use of pharmacotherapy. Results. Safety analysis found no differences between groups. During 28 days period a higher incidence of ARVI, including COVID-19, was observed in the group of comparison (13 vs 3 cases in the study group). The odd ratio was 0.224 (95 % CI: 0.040-0.826), p = 0.020. The total number of ARVI cases, including COVID-19, in the group of comparison during 2 months of research was 26 vs 6 in the study group. The odd ratio was 0.233 (95 % CI: 0.077- 0.594), p = 0,001. The longest period of persistence of respiratory symptoms was obtained in the group of comparison (7 vs 4 days in the study group, p = 0.034). Conclusion. Nasal interferon-gamma as a preventive measure contributes to a decrease of infection incidence of ARVI, including COVID-19.
背景。体外研究表明，在外源性干扰素预处理的情况下，有效的病毒感染阻断。干扰素- γ是一种独特的免疫干扰素，在急性呼吸道病毒感染(ARVI)患者中积极表达，保护身体免受严重感染。目的:评价鼻用γ干扰素预防ARVI(包括COVID-19)的安全性和有效性。材料和方法。该研究招募了630名成年志愿者，他们的PCR检测结果为SARS-CoV-2阴性，没有呼吸道症状和干扰素的禁忌症。参与者被随机(1:1)分为两组:研究组-使用预防性鼻干扰素- γ疗程，对照组-不使用预防性疗程。所有参与者都被给予日记，用于每日监测呼吸系统症状、不良事件，并记录药物治疗的使用情况。结果。安全性分析没有发现组间差异。在28天期间，对照组观察到包括COVID-19在内的ARVI发病率较高(13例vs研究组3例)。奇比为0.224 (95% CI: 0.040-0.826)， p = 0.020。在2个月的研究期间，对照组包括COVID-19在内的ARVI病例总数为26例，而研究组为6例。奇比为0.233 (95% CI: 0.077 ~ 0.594)， p = 0.001。对照组呼吸系统症状持续时间最长(7天vs研究组4天，p = 0.034)。结论。鼻用干扰素作为预防措施有助于降低ARVI感染的发生率，包括COVID-19。
{"title":"Preventive effectiveness of nasal interferon-gamma among adult volunteers against acute respiratory viral infections, including COVID-19","authors":"P. A. Talyzin, A. Myasnikov, S. Berns, M. Ilyina, A. Komazov, V. Lynyov, E. V. Ekusheva","doi":"10.33029/0206-4952-2022-43-3-301-311","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-3-301-311","url":null,"abstract":"Background. In vitro studies showed effective viral infection block in case of pretreatment with exogenous interferons. Interferon-gamma is a unique immune interferon, actively expressed in patients with acute respiratory viral infections (ARVI) and defending the body from severe infection course. Aim - to evaluate the safety and preventive effectiveness of nasal interferon-gamma protecting against ARVI, including COVID-19. Material and methods. The study enrolled 630 adult volunteers with a negative PCR test result for SARS-CoV-2, without respiratory symptoms and contraindications to interferongamma. Participants were randomized (1 : 1) into 2 groups: the study group - with the use of a prophylactic course of nasal interferon-gamma, and the group of comparison - without a course of prophylaxis. All participants were given a diary for daily monitor respiratory symptoms, adverse events, and record the use of pharmacotherapy. Results. Safety analysis found no differences between groups. During 28 days period a higher incidence of ARVI, including COVID-19, was observed in the group of comparison (13 vs 3 cases in the study group). The odd ratio was 0.224 (95 % CI: 0.040-0.826), p = 0.020. The total number of ARVI cases, including COVID-19, in the group of comparison during 2 months of research was 26 vs 6 in the study group. The odd ratio was 0.233 (95 % CI: 0.077- 0.594), p = 0,001. The longest period of persistence of respiratory symptoms was obtained in the group of comparison (7 vs 4 days in the study group, p = 0.034). Conclusion. Nasal interferon-gamma as a preventive measure contributes to a decrease of infection incidence of ARVI, including COVID-19.","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.33029/0206-4952-2022-42-6-621-631
O. Elisyutina, N. Shershakova, V. Smirnov, I. Shilovskiy, A. Korneev, A. Poroshina, E. V. Smolnikov, A. Litovkina, E.S. Fedenko , D. Kudlay, R. Valenta, M. Khaitov
{"title":"New approaches to allergen-specific immunotherapy (ASIT): development of a recombinant vaccine against birch pollen allergy","authors":"O. Elisyutina, N. Shershakova, V. Smirnov, I. Shilovskiy, A. Korneev, A. Poroshina, E. V. Smolnikov, A. Litovkina, E.S. Fedenko , D. Kudlay, R. Valenta, M. Khaitov","doi":"10.33029/0206-4952-2022-42-6-621-631","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-42-6-621-631","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.33029/0206-4952-2022-43-1-18-32
I. V. Andreev, K.O. Nechay, A. I. Andreev, A.P. Zubaryova, D. R. Esaulova, A.M. Alenova, I.А. Nikolaeva , O. P. Chernyavskaya, K. S. Lomonosov, A. Shulzhenko, O. Kurbacheva, E. Latysheva, N. Shartanova, E. Nazarova, L. Romanova, N. Cherchenko, V. Smirnov, O. Averkov, А. Martynov, V. Vechorko, G. Gudima, D. Kudlay, R. Khaitov, M. Khaitov
Introduction. Mass vaccination of the population against SARS-CoV-2 in Russia and abroad has been going on for more than 2 years. Various types of vaccines are used for vaccination (vector vaccines, RNA vaccines, whole-virion vaccines). The first in the world was registered the Russian vector vaccine «Gam-COVID-Vac» («Sputnik V»), which is widely used in our country, as well as in many other countries of the world. An important area of research is the monitoring of the parameters of the vaccine-induced immune response their analysis in relation to the characteristics of the immune response caused by SARSCoV-2 infection/COVID-19. Such studies are important both for assessing the intensity and duration of post-vaccination immunity, and for improving strategies for immunoprophylaxis and immunotherapy of coronavirus infection. The article presents the results of a study of the humoral immune response in patients with COVID-19 and vaccinated with «Sputnik V» in the period from autumn 2020 till the present time. The aim of the work - a comparative study of the humoral immune response to SARSCoV-2 infection and vaccination against COVID-19. Material and methods. The content of antibodies against SARS-CoV-2 S- and N-proteins was studied in 449 blood serum samples of men and women (age 25-65 years). 5 groups of samples were formed: suffered from COVID-19 of mild and moderate severity, at different times after recovery (262 samples);immunized with the «Sputnik V» vaccine, at different times after injection of the 2nd component of «Sputnik V» (104 samples);suffered from COVID-19 of mild and moderate severity, and then vaccinated with «Sputnik V» (53 samples);vaccinated with «Sputnik V», and then suffered with COVID-19 (12 samples);revaccinated with the vaccine «Sputnik Light» (18 samples). Results. To assess the content of IgG antibodies to S-protein and to N-protein of SARSCoV-2 in human blood sera, an EIA diagnostic system was developed further certified by the Ministry of Health of Russian Federation. In people suffered COVID-19 in 90 % of cases the positive levels of IgG antibodies to SARS-CoV-2 S-protein persist 9 months after recovery, while the proportion of potential plasma donors and material for obtaining intravenous immunoglobulin with a high content of IgG antibodies to S-protein 1 month after the disease is 20 %. In 76 % of people vaccinated with «Sputnik V» high levels of IgG antibodies to S-protein are detected within 6 months after the course of vaccination. The content of IgG antibodies to S-protein in the blood sera of persons suffered COVID-19, and then 6 months after recovery vaccinated with the 1st component of the vaccine «Sputnik V» in 100 % of cases was high with a positivity coefficient above 8.1, regardless of the initial value, already on 7 and 21 days after injection. In persons vaccinated with «Sputnik V» and then passed COVID-19, a high content of S-specific IgG antibodies is observed in 100 % of cases. The examination of vacci
{"title":"Post-vaccination and post-infection humoral immune response to the SARS-CoV-2 infection","authors":"I. V. Andreev, K.O. Nechay, A. I. Andreev, A.P. Zubaryova, D. R. Esaulova, A.M. Alenova, I.А. Nikolaeva , O. P. Chernyavskaya, K. S. Lomonosov, A. Shulzhenko, O. Kurbacheva, E. Latysheva, N. Shartanova, E. Nazarova, L. Romanova, N. Cherchenko, V. Smirnov, O. Averkov, А. Martynov, V. Vechorko, G. Gudima, D. Kudlay, R. Khaitov, M. Khaitov","doi":"10.33029/0206-4952-2022-43-1-18-32","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-1-18-32","url":null,"abstract":"Introduction. Mass vaccination of the population against SARS-CoV-2 in Russia and abroad has been going on for more than 2 years. Various types of vaccines are used for vaccination (vector vaccines, RNA vaccines, whole-virion vaccines). The first in the world was registered the Russian vector vaccine «Gam-COVID-Vac» («Sputnik V»), which is widely used in our country, as well as in many other countries of the world. An important area of research is the monitoring of the parameters of the vaccine-induced immune response their analysis in relation to the characteristics of the immune response caused by SARSCoV-2 infection/COVID-19. Such studies are important both for assessing the intensity and duration of post-vaccination immunity, and for improving strategies for immunoprophylaxis and immunotherapy of coronavirus infection. The article presents the results of a study of the humoral immune response in patients with COVID-19 and vaccinated with «Sputnik V» in the period from autumn 2020 till the present time. The aim of the work - a comparative study of the humoral immune response to SARSCoV-2 infection and vaccination against COVID-19. Material and methods. The content of antibodies against SARS-CoV-2 S- and N-proteins was studied in 449 blood serum samples of men and women (age 25-65 years). 5 groups of samples were formed: suffered from COVID-19 of mild and moderate severity, at different times after recovery (262 samples);immunized with the «Sputnik V» vaccine, at different times after injection of the 2nd component of «Sputnik V» (104 samples);suffered from COVID-19 of mild and moderate severity, and then vaccinated with «Sputnik V» (53 samples);vaccinated with «Sputnik V», and then suffered with COVID-19 (12 samples);revaccinated with the vaccine «Sputnik Light» (18 samples). Results. To assess the content of IgG antibodies to S-protein and to N-protein of SARSCoV-2 in human blood sera, an EIA diagnostic system was developed further certified by the Ministry of Health of Russian Federation. In people suffered COVID-19 in 90 % of cases the positive levels of IgG antibodies to SARS-CoV-2 S-protein persist 9 months after recovery, while the proportion of potential plasma donors and material for obtaining intravenous immunoglobulin with a high content of IgG antibodies to S-protein 1 month after the disease is 20 %. In 76 % of people vaccinated with «Sputnik V» high levels of IgG antibodies to S-protein are detected within 6 months after the course of vaccination. The content of IgG antibodies to S-protein in the blood sera of persons suffered COVID-19, and then 6 months after recovery vaccinated with the 1st component of the vaccine «Sputnik V» in 100 % of cases was high with a positivity coefficient above 8.1, regardless of the initial value, already on 7 and 21 days after injection. In persons vaccinated with «Sputnik V» and then passed COVID-19, a high content of S-specific IgG antibodies is observed in 100 % of cases. The examination of vacci","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.33029/0206-4952-2022-43-4-412-422
V. Talayev, I. Zaichenko, M. Svetlova, E. Voronina, O. Babaykina, I. Soloveva, I. Belova, A. G. Tochilina
{"title":"Interaction of dendritic cells with microorganisms capable of colonizing the intestine","authors":"V. Talayev, I. Zaichenko, M. Svetlova, E. Voronina, O. Babaykina, I. Soloveva, I. Belova, A. G. Tochilina","doi":"10.33029/0206-4952-2022-43-4-412-422","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-4-412-422","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.33029/0206-4952-2022-43-6-702-713
Ye.N. Bogomyagkova, A. Solpov, P. Tereshkov, N.G. Trushina, Y. Vitkovskiy
{"title":"The content of platelet-leukocyte coaggregates in the peripheral blood of healthy children of different ages","authors":"Ye.N. Bogomyagkova, A. Solpov, P. Tereshkov, N.G. Trushina, Y. Vitkovskiy","doi":"10.33029/0206-4952-2022-43-6-702-713","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-6-702-713","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69482823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.33029/0206-4952-2022-43-6-736-745
I. M. Bogdanova, K. Artemieva, M. N. Boltovskaya, M. Kondashevskaya, N. V. Nizyaeva
{"title":"Mast cell involvement in physiological and preeclampsia complicated pregnancy","authors":"I. M. Bogdanova, K. Artemieva, M. N. Boltovskaya, M. Kondashevskaya, N. V. Nizyaeva","doi":"10.33029/0206-4952-2022-43-6-736-745","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-6-736-745","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69482878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.33029/0206-4952-2022-43-3-266-276
V. Talayev, E. Voronina, M. Svetlova, I. Zaichenko, O. Babaykina
{"title":"Effects of interaction between circulating CD4+CCR6+ T cells and B-lymphocytes","authors":"V. Talayev, E. Voronina, M. Svetlova, I. Zaichenko, O. Babaykina","doi":"10.33029/0206-4952-2022-43-3-266-276","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-43-3-266-276","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.33029/0206-4952-2022-42-6-643-653
E. A. Lysenko, V. A. Shmarov, M. Rykova, E. Antropova, O. Kutko, S. Shulgina, K. Orlova, E.A. Zhirova, A. Sadova, D. D. Vlasova, S. Ponomarev
{"title":"The influence of respiratory hypoxic gas mixtures (oxygen-nitrogen and oxygen-nitrogen-argon) in a pressure chamber on the state of the human cellular immunity","authors":"E. A. Lysenko, V. A. Shmarov, M. Rykova, E. Antropova, O. Kutko, S. Shulgina, K. Orlova, E.A. Zhirova, A. Sadova, D. D. Vlasova, S. Ponomarev","doi":"10.33029/0206-4952-2022-42-6-643-653","DOIUrl":"https://doi.org/10.33029/0206-4952-2022-42-6-643-653","url":null,"abstract":"","PeriodicalId":38750,"journal":{"name":"Immunologiya","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69481786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：